The global medical foods market is projected to expand by 6.5% from 2023 to 2030. Increasing communicable and non-communicable diseases and efforts to treat them nutritionally are expected to fuel market growth in the coming years. Increased chronic disease incidence, a growing elder population that prefers medicinal meals, and a better grasp of clinical nutrition among healthcare professionals and patients are driving growth. The share of the global population over 60 will double between 2015 and 2050, according to the WHO. The expanding older population suffering from dementia, stroke, multiple sclerosis, and problems swallowing requires specific nutritional treatment, which is expected to boost the market during the forecast period.
Crohn's disease and ulcerative colitis diagnoses are rising. Because of this, medical food products are needed worldwide. According to the Crohn's and Colitis Foundation of America, 1.6 million Americans have Crohn's or ulcerative colitis. Over 70,000 new instances of Crohn's disease and ulcerative colitis are diagnosed annually in the U.S. According to the National Renal Foundation, chronic kidney disease affects 10% of the global population annually. According to the CDC, more than 20 million Americans have chronic renal illness each year (CDC). Medical foods are developed to cure specific disorders by managing specific dietary parameters. These disorders should boost the market growth.
Browse for report at : https://www.acutemarketreports.com/report/medical-foods-market
Growing product launch activities and product development advancements will drive demand for medicinal foods. To treat new genetic metabolic disorders and control their incurable condition, new medical foods are in demand. Nestle Health Science introduced a ready-to-drink protein meal for medical disorders in China in October 2020. (FSMPs). This drink contains galactomannan, a soluble dietary fibre that helps alleviate GI intolerance and diarrhoea. Medicinal meals to manage diabetic neuropathy and diabetes may further boost the industry. Diabetes is a major chronic disease whose incidence has risen in recent decades. Diabetes is the tenth leading cause of death in the world, according to WHO. Diabetes causes 1.5 million deaths. An unhealthy lifestyle and diet create diabetic neuropathy, and medicinal foods treat and manage it. According to the International Diabetic Federation, 463 million adults have diabetes in 2019 and 700 million by 2045.
UK’s medical insurance companies are worried about escalating insurance claims. As a result, medical foods companies, such as Galen, aim to release PKU EASY Microtabs in February 2020 for metabolic condition patients. These products are helping the medical foods sector grow to $35 billion by 2030. Metabolism-related medical food sales are expected to skyrocket. Pharmaceutical businesses are creating novel, more appetising protein substitutes. These cutting-edge protein replacements are promoted for youngsters 8 and older to help treat chronic medical conditions including phenylketonuria. Because many infants are born with genetic metabolic problems, firms are focusing more on protein alternatives.
Medicinal food regulations, such as adulteration prevention and CGMP compliance, provide a licencing challenge. As a result, medical food companies are referring more to FDA recommendations (Food and Drug Association). These recommendations highlight some manufacturing questions. These FAQs and ideas help producers understand the laws. By using post-market enforcement tactics like adverse event report monitoring, the FDA ensures that customers obtain high-quality products. In order to comply with food safety regulations, companies are using post-market enforcement.
Poor diet, chronic ailments, or digestive system issues may cause malnutrition. Malnutrition slows wound healing, reduces functional status, impairs immune function, and prolongs recovery from illness. Oncology patients risk malnutrition. Multiple studies have found that malnutrition burdens the world's healthcare systems because it affects 70% of hospitalised patients. Longer hospital stays and more frequent visits contribute to the high financial burden. Parenteral feeding is crucial for malnourished patients. Enteral nutrition cannot supply these patients' nutritional needs. Malnutrition and nutrition for cancer therapy are expected to drive the global market.
The market for medicinal meals is expanding into areas without nutritional care. Few enterprises dominate the market. The US and Europe have the world's largest therapeutic food markets. Depending on the reimbursement scheme, insurance companies may or may not cover prescription drugs. Insurance-mandated medical food reimbursement laws create a favourable environment for market-active companies. These efforts affect the market as a whole, and market participants benefit from favourable initiatives. Policy differences allow producers to cut the pricing of medical food products, making them more affordable for clients and facilitating market penetration. Insurance companies have long opposed such limitations for medical foods because it would reduce their earnings. Medical meal rules and standards are lacking, complicating the problem. This could make it easy to include non-medicinal foods on the list.
Oral had a market share of almost 68% in 2021, making it the dominant segment. Oral administration of therapeutic meals is projected to propel the industry in the coming years. Doctors prescribe powder formulations. Since these formulations can be given enterally and orally to patients of any age, they should boost the segment. Manufacturers also develop customer-preferred therapeutic foods. Danone introduced Souvenaid, a powdered medicinal nutrition drink, in 2023.
Pill’s segment is expected to have the highest CAGR during the forecast period of 2023 to 2030. 2021 revenue was primarily dominated by the powder segment. Consumers' growing awareness of the benefits of medical food products, such as the fact that they contain a combination of vitamins and minerals and are designed to alleviate nutritional deficiencies, is helping to expand this market segment. This product category is easy to consume, which contributes to its popularity among the young and old.
Chemotherapy-induced diarrhoea accounted for 15.0% of revenue in 2021 and thereby remained the most dominant market. Diarrhoea can affect chemotherapy and dosing. Increasing demand for medicinal foods in dietary control should boost the segment's growth. Chemotherapy-induced diarrhoea is also associated with irinotecan and fluoropyrimidines. Chemotherapy with cytotoxic drugs can cause severe diarrhoea in 5% to 44% of patients, depending on timing and pharmacological agents. Medical meals are key to managing and treating this type of diarrhoea. Due to loss of absorptive surfaces and mucosal damage from chemotherapy-related diarrhoea, patients should eat easy-to-digest therapeutic meals. This will propel category growth in the next years. To halt diarrhoea, patients must cease taking their medicine and take clear liquid medical meals under a doctor's supervision. This rests the bowels. In the coming years, demand for medical meals to treat chemotherapy-induced diarrhoea is expected to grow.
Due to the rise in diabetes and the number of individuals at risk for diabetic neuropathy has also raise over the decade. Therefore, the diabetic neuropathy segment is expected to have the greatest CAGR during the forecast period. Numerous initiatives for nutritional diabetes treatment are fuelling the market growth. Increased use of medical foods containing vitamin B-12, omega-3 fatty acids, and lipoid acid to address diabetic neuropathy will drive segment expansion in the future. This choice may improve diabetic neuropathy. The rise in diabetic neuropathy sufferers and prescriptions for medicinal meals to manage the ailment are also fuelling this market's growth. Increasing diabetic neuropathy in every region of the world also drives growth. A 2019 study by Current Diabetes Reports indicated that diabetic peripheral neuropathy affects 50% of diabetics over their lifetime.
Institutional sales contributed 35% of overall revenue in 2021. Increasing patient visits to hospitals and other healthcare facilities for the diagnosis and treatment of chronic and dietary illnesses is driving the market growth. Doctors may propose medical foods to treat or manage a patient's condition. Growing patient preference for hospital-based chronic illness treatment would increase demand for services in this market category. The expansion of private and public healthcare facilities and the rise in chronic disease patients will boost this market segment globally. Online sales are expected to grow fastest during the predicted period. Buying medicinal foods online is popular due to its convenience. The fact that medicinal foods are developed for long-term nutrition control has contributed to a boom in internet sales. As e-commerce grows, more people are buying medicinal foods online, which creates opportunities for market growth.
North America contributed 35.0% of 2021 revenue. Abbott Laboratories and Mead Johnson & Company make a lot of revenue, which drives the market. National Health Council says 40% of Americans have chronic illnesses. Diabetes, heart disease, and despair plague Americans. The U.S. also has a rising cancer rate. This has led people to invest in medical food products for a healthy lifestyle that helps with illness and immunity. Asia-Pacific will have the fastest growth rate from 2023 to 2030. This is attributable to the rising number of cancer and diabetes patients and government healthcare efforts. Janssen reports that half of all newly diagnosed cancer cases occur in Asia-Pacific. According to the study, cancer deaths in the Asia Pacific are estimated to rise by 36% by 2030, which will enhance the market growth in the region. A growing population and higher awareness among chronic disease patients to eat medicinal food for improved health management are expected to drive the Asia Pacific market. The local presence of key companies and undeveloped regional opportunities also stimulate regional market growth.
The market remains consolidated with top market players contributing over 70% of market revenues in 2021. Nestlé S.A., Abbott, and Danone S.A. account for most medicinal meal revenue. Targeted Medical Pharma Inc., Primus Pharmaceuticals Inc., Fresenius Kabi AG and others are smaller medical food companies. Several industry consolidation activities by clinical nutrition producers should also boost the market in the next years. Manufacturers' acquisitions, mergers, product launches, and partnerships are expected to drive market growth in the coming years. Nestlé acquired Zenpen in January 2020 to expand its clinical nutrition business. Growing demand for medical meals from patients and healthcare professionals, as well as market consolidation to maintain a strong position, have led to heated competition among market competitors. Leading corporations have invested heavily in product development and global expansion to increase their revenue share. Top players are also seeking strategic acquisitions, mergers, and partnerships to diversify their product offerings and enhance their market share.
